Evidence map›Paper›PMID 37350805›Full record

ArticleWorld journal of oncology2023

Synchronous Bilateral Breast Cancer With Discordant Receptor Status: Treating One Patient but Two Diseases.

Ademola S Ojo, Adedoyin Shittu, Stacy Amadife, Devon Jackson, Mica Grantham, Ahmed Ali, Ravi Sarma

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ademola S OjoDepartment of Internal Medicine, Howard University Hospital, Washington, DC, USA.
Adedoyin ShittuDepartment of Internal Medicine, Howard University Hospital, Washington, DC, USA.
Stacy AmadifeDepartment of Internal Medicine, Howard University Hospital, Washington, DC, USA.
Devon JacksonDepartment of Pathology, Howard University Hospital, Washington, DC, USA.
Mica GranthamDepartment of Pathology, Howard University Hospital, Washington, DC, USA.
Ahmed AliHoward University Cancer Center, Washington, DC, USA.
Ravi SarmaHoward University Cancer Center, Washington, DC, USA.
Howard University Hospital · USHoward University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The expression of hormone receptors (estrogen and progesterone) and human epidermal growth factor receptor-2 (HER2) has been used for both therapeutic and prognostic purposes in the management of breast cancer. The presence of a discordant receptor status complicates the approach to treatment in patients with synchronous bilateral breast cancer. We describe the case of a 45-year-old female with synchronous bilateral breast cancer with a triple-negative tumor and a contralateral HER2-positive tumor and discussed the impact of this on the approach to therapeutic management.

Indexed as

Breast cancerEstrogen receptorHuman epidermal growth factor receptorProgesterone receptor

Identifiers

PMID37350805
PMCPMC10284639
OpenAlexW4380224531

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.